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3.72G0.32, respectively, P!0.001), had decreased proliferation in pancreatic
(0.35G0.03% (pasireotide) vs. 0.78G0.08% (PBS)) and pituitary (0.73G0.07%
(pasireotide) vs. 1.81G0.15% (PBS)) NETs (both P!0.0001), but had increased
apoptosis in pancreatic (0.42G0.05% (pasireotide) vs. 0.19G0.03% (PBS)) and
pituitary (14.75G1.58% (pasireotide) vs. 2.35G0.44% (PBS)) NETs (both
P!0.001). Thus in summary, pasireotide treatment increased survival byw20%
and inhibited pancreatic and pituitary NET growth, indicating its potential as an
anti-proliferative and pro-apoptotic therapy for pancreatic and pituitary NETs.
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Steroid sulphatase and G-protein coupled oestrogen receptor in human
colorectal cancer: correlation with late-stage disease and potential
therapeutic targets
Habibur Rahman, Lorna Gilligan, Anne-Marie Hewitt, Dion Morton &
Paul Foster
Institute of Metabolism and Systems Research, University of Birmingham,
Birmingham, West Midlands, UK.
Steroid sulphatase (STS) liberates sulphated oestrogens into their active forms.
In the colon, evidence suggests that although initially pro-apoptotic in healthy
mucosa, once malignancy occurs, oestrogens may stimulate colorectal cancer
(CRC) proliferation. Moreover, greater intratumoural oestrogen synthesis is
negatively associated with survival outcomes in CRC patients. However, little is
known about oestrogen metabolism pathways in CRC, and whether alterations in
local oestrogen synthesis and actions relate to clinical and pathological features.
Furthermore, it is unknown whether manipulation of oestrogen pathways has
therapeutic potential. Therefore, using qRT-PCR and immunoblotting, in healthy
human colorectal tissue matched with CRC samples (nZ56) we correlate the
dysregulation of key oestrogen synthesis enzymes (steroid sulphatase (STS), 17b-
hydroxysteroid dehydrogenase (17bHSD) type-1, type-2, type-7, and type-12)
and the G-protein coupled oestrogen receptor (GPER), with patient TNM staging,
lymph node infiltration, and distant metastases. In addition, ELISA assays were
undertaken to ascertain the effects of oestrogens on proliferation of CRC cell
lines. STS activity, 17bHSD7, and 17bHSD12 expression all showed a positive
correlation with TNM staging in patient CRC samples, indicating greater
oestrogen availability is linked to advanced stage disease. Increased GPER
expression also significantly (P!0.05) correlated with late-stage malignancy. In
CRC cell lines, over-expression of STS significantly (P!0.01) increased cell
proliferation when treated with sulphated oestrogens. This effect was completely
ablated when treated in combination with the STS inhibitor STX64 (P!0.001).
Furthermore, we show here for the first time that the GPER agonist, G1, also
stimulated CRC proliferation; with both oestrogen and G1 effects significantly
inhibited with the GPER selective antagonist G15 (P!0.001). Increased STS
activity and GPER expression are associated with late-stage CRC, strongly
suggesting a role for oestrogens in this malignancy. Thus, reducing the
availability and action of oestrogens by inhibiting STS and GPER, respectively,
may have therapeutic benefits for patients with CRC.
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PTTG is phosphorylated at residue T60 and regulates p53 stability, in
conjunction with PBF, in head and neck cancer
Bhavika Modasia1, Martin L Read1, Vicki E Smith1, Andy S Turnell2,
Peter C Rae3, Rachel J Watkins3, Waraporn Imruetaicharoenchoke1,
Vikki L Poole1, Hisham Mehanna3 & Chris J McCabe1
1Centre for Endocrinology, Diabetes and Metabolism, Institute of
Metabolism and Systems Research, University of Birmingham,
Birmingham, UK; 2School of Cancer Sciences, University of Birmingham,
Birmingham, UK; 3Institute of Head and Neck Studies and Education,
University of Birmingham, Birmingham, UK.
PTTG is a multifunctional proto-oncogene, overexpressed in thyroid, pituitary
and other endocrine cancers. PTTG is also implicated in the pathogenesis of head
and neck cancer, where high PTTG expression independently correlates with
advanced tumour stage and reduced disease-free survival. Recently, abrogation of
residue threonine-60 (T60) has been associated with altered PTTG half-life,
chromosomal instability and cell invasion. We therefore generated a phospho-
specific antibody against T60 PTTG. Transient transfection of wild-type PTTG
resulted in a significant increase in T60-phosphorylated PTTG protein expression
in HeLa cells (3-fold, pZ0.001), which was blocked by a phospho-peptide.
Detection was also lost with a PTTG-T60 mutant (T60A). Antibody specificity
was further confirmed by immunoprecipitation assays. Paraffin-embedded
formalin-fixed tumour sections were obtained for immunohistochemical analysis
from patients with primary oropharyngeal squamous cell carcinoma. Abundant
total PTTG protein expression was evident both in the cytoplasm and nucleus. In
contrast, expression of T60-phosphorylated PTTG was predominantly nuclear. As
interaction with its binding partner PBF facilitates PTTG nuclear localisation, and
both proto-oncogenes alter p53 stability and function, we assessed the relative
contributions of PTTG and PBF to p53 stability. Preliminary experiments
demonstrated that transfection of wild-type PBF or PTTG into HPV-positive
93-VU-147T HNSCC cells decreased p53 protein levels compared to controls.
Further, half-life studies demonstrated reduced p53 stability in 93-VU-147T cells
transfected with either PBF or PTTG. Interestingly, transfection with a PBF
mutant incapable of PTTG interaction, or a PTTG mutant unable to bind PBF,
resulted in an initial decrease in p53 stability followed by subsequent
stabilisation. These data indicate a potential role for both PTTG and PBF in
modulation of p53 stability in head and neck cancers. Furthermore, PTTG is
phosphorylated at residue T60 in head and neck tumours, which may alter its well
described mitotic regulatory function.
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Functional disruption of the tumour suppressor p53 has a critical role in
promoting the development of most cancers. The proto-oncogenes PBF and
PTTG1 both regulate p53 activity, but the relative contribution of each gene in
influencing p53 function has not been delineated, especially in thyroid cancer
where both proto-oncogenes are commonly overexpressed. To better understand
the interplay between PTTG1, PBF and p53 in vivo, we examined p53 responses
in primary thyrocytes cultured from transgenic mice overexpressing PBF (PBF-
Tg) and PTTG1 (PTTG-Tg), either singly or in combination in a bi-transgenic
murine model (Bi-Tg). Western blotting showed that p53 and g-H2AX protein
levels were elevated in PTTG1-Tg and BI-Tg thyrocytes (O2-fold; P!0.05). In
contrast, no significant increase was observed in p53 or g-H2AX levels in PBF-Tg
thyrocytes compared toWT (PZNS). Consistent with this, a greater proportion of
a panel of p53-responsive DNA repair genes were significantly down-regulated in
PTTG1-Tg (30/83 genes) and BI-Tg (30/83 genes) than in PBF-Tg thyrocytes
(12/83 genes). A differential p53 response was further evident following gamma-
irradiation of cells, with fewer significant mRNA changes occurring in PTTG1-
Tg (0/10 genes; PZNS) and BI-Tg (4/10 genes; P!0.05) than in WT primary
thyrocytes (10/10 genes; P!0.01). By comparison, irradiation of PBF-Tg
thyrocytes gave the greatest reduction in mRNA levels (6/10 genes; P!0.05) for
genes such as Chek1 (4.4-fold; P!0.01) and Rad51 (8.4-fold; P!0.01). We
therefore examined potential associations between PBF and DNA repair genes in
human thyroid tumours. Importantly, a significant correlation was apparent
between PBF and Chek1 (RZ0.44; P!0.05; NZ22), Fancg (RZ0.78; P!0.001;
NZ22) and Mutyh (RZ0.62; P!0.05; NZ22). Together our data reveal for the
first time that PBF and PTTG1 mediate distinct p53 response profiles in vivo.
These results offer important insights for understanding the impact of proto-
oncogenes on thyroid tumorigenesis and for identifying new tumour biomarkers.
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Follow up of differentiated thyroid cancer survivors during pregnancy:
a retrospective analysis
Rhodri King, Medha Rathod & Emma Ward
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Differentiated thyroid cancer (DTC) is common in female patients of reproductive
age and generally has a good prognosis and so many patients may become
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